

**Listing of the Claims:**

**1. (Canceled)**

**2. (Canceled)**

**3. (Currently Amended)** A method of treating diabetes and/or microvascular diabetic complications comprising administering C-peptide or a pharmaceutical composition comprising C-peptide to a patient once daily; wherein said once daily administration does not include a continuous administration or the presence of release rate-controlling agents, and wherein said administration is by subcutaneous administration, and wherein said pharmaceutical composition contains 100 to 1800 nmol of C-peptide.

**4. (Canceled)**

**5. (Canceled)**

**6. (Canceled)**

**7. (Canceled)**

**9. (Canceled)**

**10. (Previously Amended)** The method according to claim 3, wherein said C-peptide is human C-peptide.

**11. (Previously Presented)** The method according to claim 3, wherein said C-peptide is a fragment EGSLQ (SEQ ID NO: 2).

**12. (Previously Amended)** The method according to claim 3, wherein said patient is a human.

**13. (Canceled)**

**14. (Previously Amended)** The method according to claim 3, wherein said C-peptide is in an aqueous solution.

**15. (Currently Amended)** The method according to claim 3 16, wherein said complications are diabetic neuropathy.

**16. (New)** The method according to claim 3, wherein said complications are diabetic nephropathy, retinopathy or neuropathy.